ALB and chronic kidney disease: The DAPA CKD trial enrolled 270 patients with IgAN who fulfilled its inclusion criteria of with GFR 25–75, urine albumin to creatinine ration 200–5,000 mg/g, stable dose of ACEI/ARB and no immunotherapy for 6 months before enrollment.